Skip to content
Lumigan(bimatoprost)
Durysta, Ganfort, Latisse, Lumigan (bimatoprost) is a small molecule pharmaceutical. Bimatoprost was first approved as Lumigan on 2001-03-16. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. The pharmaceutical is active against prostaglandin F2-alpha receptor. In addition, it is known to target aldo-keto reductase family 1 member C3.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Durysta, Latisse, Lumigan (generic drugs available since 2014-12-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bimatoprost
Tradename
Company
Number
Date
Products
LATISSEAbbVieN-022369 RX2008-12-24
1 products, RLD, RS
DURYSTAAbbVieN-211911 RX2020-03-04
1 products, RLD, RS
LUMIGANAllerganN-022184 RX2010-08-31
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bimatoprostANDA2023-05-27
durystaNew Drug Application2020-11-09
latisseNew Drug Application2020-09-14
lumiganNew Drug Application2022-03-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
open-angle glaucomaEFO_0004190D005902H40.1
Agency Specific
FDA
EMA
Expiration
Code
BIMATOPROST, DURYSTA, ABBVIE
2023-03-04NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Bimatoprost, Durysta, Abbvie
94923162034-10-31DP
99809742034-10-31U-2759
86291852031-07-15DS, DP
77993362029-04-24DP
82067372027-04-07U-2759
91494282026-12-19DP
104415432026-12-19DP
86733412025-02-19U-2759
103987072024-04-30U-2759
Bimatoprost, Lumigan, Allergan
78515042027-06-13DS, DP
82783532025-03-16DP
82991182025-03-16U-1295
83096052025-03-16U-1293, U-1294
83384792025-03-16DPU-1295
85247772025-03-16U-1235
85866302025-03-16U-1458
87723382025-03-16DPU-1528
89331202025-03-16DP
89331272025-03-16DP
91557162025-03-16DPU-1528
92419182025-03-16DPU-1814
Bimatoprost, Latisse, Abbvie
81011612024-05-25U-1217, U-1218
80389882023-08-25DS, DPU-1208
82630542023-01-15U-1277
86327602023-01-15U-1487
87587332023-01-15U-1487
89867152023-01-15U-1217
92161832023-01-15U-1487
92269312023-01-15U-1799
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EE: Prostaglandin analogues, antiglaucoma drugs and miotics
— S01EE03: Bimatoprost
HCPCS
Code
Description
J7351
Injection, bimatoprost, intracameral implant, 1 microgram
Clinical
Clinical Trials
141 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ocular hypertensionD009798EFO_1001069H40.041824251581
Open-angle glaucomaD005902EFO_0004190H40.131213141453
GlaucomaD005901EFO_0000516H40151022239
HypotrichosisD007039—155213
Graves ophthalmopathyD049970EFO_10014661—11—3
Alopecia areataD000506EFO_0004192L6311—113
VitiligoD014820EFO_0004208L801——1—2
Low tension glaucomaD057066EFO_1001022H40.12———2—2
Intraocular pressureD007429———112
Macular edemaD008269———1—1
Show 3 more
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AlopeciaD000505HP_0002293L6434——18
Migraine disordersD008881EFO_0003821G43—1———1
Headache disordersD020773EFO_0009550G44—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50————11
HypertrichosisD006983L68————11
Angle-closure glaucomaD015812————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBIMATOPROST
INNbimatoprost
Description
Bimatoprost is a monocarboxylic acid amide. It has a role as an antiglaucoma drug and an antihypertensive agent.
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1
Identifiers
PDB2F38
CAS-ID155206-00-1
RxCUI283810
ChEMBL IDCHEMBL1200963
ChEBI ID51230
PubChem CID5311027
DrugBankDB00905
UNII IDQXS94885MZ (ChemIDplus, GSRS)
Target
Agency Approved
PTGFR
PTGFR
Organism
Homo sapiens
Gene name
PTGFR
Gene synonyms
NCBI Gene ID
5737
Protein name
prostaglandin F2-alpha receptor
Protein synonyms
FP prostanoid receptor, PGF receptor, PGF2 alpha receptor, prostaglandin receptor (2-alpha), Prostanoid FP receptor
Uniprot ID
Q9P1X4
Mouse ortholog
Ptgfr (19220)
prostaglandin F2-alpha receptor (P43117)
Alternate
AKR1C3
AKR1C3
Organism
Homo sapiens
Gene name
AKR1C3
Gene synonyms
DDH1, HSD17B5, KIAA0119, PGFS
NCBI Gene ID
8644
Protein name
aldo-keto reductase family 1 member C3
Protein synonyms
17-beta-HSD 5, 17-beta-hydroxysteroid dehydrogenase type 5, 3-alpha hydroxysteroid dehydrogenase, type II, 3-alpha-HSD type 2, 3-alpha-HSD type II, brain, 3-alpha-hydroxysteroid dehydrogenase type 2, Chlordecone reductase homolog HAKRb, DD-3, DD3, Dihydrodiol dehydrogenase 3, Dihydrodiol dehydrogenase type I, dihydrodiol dehydrogenase X, HA1753, indanol dehydrogenase, PGFS, Prostaglandin F synthase, Testosterone 17-beta-dehydrogenase 5, trans-1,2-dihydrobenzene-1,2-diol dehydrogenase, type IIb 3-alpha hydroxysteroid dehydrogenase
Uniprot ID
P42330
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,742 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,247 adverse events reported
View more details